Literature DB >> 9371901

Clinical and molecular features of spinocerebellar ataxia type 6.

G Stevanin1, A Dürr, G David, O Didierjean, G Cancel, S Rivaud, A Tourbah, J M Warter, Y Agid, A Brice.   

Abstract

The mutation involved in spinocerebellar ataxia type 6 (SCA6) is a small CAG expansion in the alpha-1A subunit of the voltage-dependent calcium channel gene. We looked for this mutation in 91 families with autosomal-dominant cerebellar ataxias and found that SCA6 is a minor locus in our series (2%) and is rare in France (1%). Furthermore, we did not detect the SCA6 mutation on 146 sporadic cases with isolated cerebellar ataxia or olivopontocerebellar atrophy. The normal and expanded alleles ranged from 4 to 15 and 22 to 28 CAG repeats, respectively, and age at onset was correlated to CAG repeat length (r = -0.87). In contrast with other SCA, the expanded allele was stable during transmission. Clinically, SCA6 patients (n = 12) presented with moderate to severe cerebellar ataxia with a lower frequency of associated signs compared with other SCA and a mean age at onset of 45 +/- 14 years (range, 24 to 67). MRI showed extensive cerebellar atrophy but not of the brainstem or cerebral cortex.

Entities:  

Mesh:

Year:  1997        PMID: 9371901     DOI: 10.1212/wnl.49.5.1243

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Autosomal dominant cerebellar ataxia type III: linkage in a large British family to a 7.6-cM region on chromosome 15q14-21.3.

Authors:  P F Worth; P Giunti; C Gardner-Thorpe; P H Dixon; M B Davis; N W Wood
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias.

Authors:  S Di Donato
Journal:  Ital J Neurol Sci       Date:  1998-12

3.  SCA 6 with Writer's Cramp: The Phenotype Expanded.

Authors:  Diana Angelika Olszewska; Richard Walsh; Tim Lynch
Journal:  Mov Disord Clin Pract       Date:  2015-08-26

Review 4.  Essential Tremor Within the Broader Context of Other Forms of Cerebellar Degeneration.

Authors:  Elan D Louis; Phyllis L Faust
Journal:  Cerebellum       Date:  2020-12       Impact factor: 3.847

Review 5.  Magnetic resonance imaging biomarkers in patients with progressive ataxia: current status and future direction.

Authors:  Stuart Currie; Marios Hadjivassiliou; Ian J Craven; Iain D Wilkinson; Paul D Griffiths; Nigel Hoggard
Journal:  Cerebellum       Date:  2013-04       Impact factor: 3.847

Review 6.  The protective role of exercise against age-related neurodegeneration.

Authors:  Alyson Sujkowski; Luke Hong; R J Wessells; Sokol V Todi
Journal:  Ageing Res Rev       Date:  2021-12-17       Impact factor: 10.895

7.  Regional features of autosomal-dominant cerebellar ataxia in Nagano: clinical and molecular genetic analysis of 86 families.

Authors:  Yusaku Shimizu; Kunihiro Yoshida; Tomomi Okano; Shinji Ohara; Takao Hashimoto; Yoshimitsu Fukushima; Shu-Ichi Ikeda
Journal:  J Hum Genet       Date:  2004-10-08       Impact factor: 3.172

Review 8.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

9.  A clinical and genetic study in a large cohort of patients with spinocerebellar ataxia type 6.

Authors:  Hiroki Takahashi; Kinya Ishikawa; Takeshi Tsutsumi; Hiroto Fujigasaki; Akihiro Kawata; Ryoichi Okiyama; Tsuneo Fujita; Kazuo Yoshizawa; Shigeki Yamaguchi; Hitoshi Tomiyasu; Fumihito Yoshii; Kazuko Mitani; Natsue Shimizu; Mineo Yamazaki; Tomoyuki Miyamoto; Tomoyuki Orimo; Shin'ichi Shoji; Ken Kitamura; Hidehiro Mizusawa
Journal:  J Hum Genet       Date:  2004       Impact factor: 3.172

Review 10.  Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics.

Authors:  Shinsuke Fujioka; Christina Sundal; Zbigniew K Wszolek
Journal:  Orphanet J Rare Dis       Date:  2013-01-18       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.